| Literature DB >> 25328519 |
Neeraj Kumar1, Anita Yadav1, Sachin Gulati1, Neeraj Aggarwal2, Ranjan Gupta3.
Abstract
In recent years, the use of organophosphorus pesticides has been extensively increased and these compounds signify a major class of agricultural pesticides today. We studied antigenotoxic potential of curcumin and carvacrol against the parathion induced DNA damage in cultured peripheral blood lymphocytes using sister chromatid exchanges as a biomarker of genotoxicity. Heparinised fresh blood from healthy individuals was treated with 2.5 μg/mL concentration of parathion in presence of curcumin and carvacrol in order to observe the antigenotoxic potential of both curcumin and carvacrol. Significant reduction (P < 0.05) was observed in the frequencies of SCEs in presence of 10 μg/mL and 15 μg/mL concentrations of curcumin as compared to parathion exposed sample. Similarly carvacrol had significant (P < 0.05) antigenotoxic effect at the concentrations of 2.5 μg/mL and 5.0 μg/mL against the parathion. We also studied the effect of GSTT1 and GSTM1 on genotoxicity of parathion and antigenotoxic potential of curcumin and carvacrol. We did not observe any significant effect (P > 0.05) of GSTT1 and GSTM1 polymorphism on genotoxicity of parathion and antigenotoxic potential of curcumin and carvacrol.Entities:
Year: 2014 PMID: 25328519 PMCID: PMC4195395 DOI: 10.1155/2014/404236
Source DB: PubMed Journal: J Toxicol ISSN: 1687-8191
Figure 1SCEs shown in untreated and parathion treated sample.
Frequency of SCE/cell in cultured human lymphocytes treated with parathion.
| Parathion treatment ( | Metaphase scored | SCE/cell ± SE |
|---|---|---|
| Untreated | 50 | 5.55 ± 0.10 |
| 0.5 | 50 | 6.43 ± 0.34 |
| 1 | 50 | 7.99 ± 0.25 |
| 2 | 50 | 10.33 ± 0.32 |
|
|
| 10.86 ± 0.40a |
| 5.0 | 50 | No differentiation |
a P < 0.05 (significance as compared to untreated).
Figure 2Induction of SCE in cultured lymphocytes by parathion. *P < 0.05 (significance as compared to untreated).
Antigenotoxic effect of curcumin against parathion treated cultured human lymphocytes.
| Treatments | Concentrations used ( | Metaphase scored | SCE/cell ± SE |
|---|---|---|---|
| Control | Untreated | 50 | 2.33 ± 0.16 |
| Parathion | 2.5 | 50 | 5.37 ± 0.36a |
| Parathion + curcumin | 2.5 + 10 | 50 | 4.59 ± 0.38b |
| Parathion + curcumin | 2.5 + 15 | 50 | 3.28 ± 0.24b |
| Curcumin | 10 | 50 | 2.41 ± 0.17c |
| Curcumin | 15 | 50 | 2.57 ± 0.13c |
| DMSO (−ve control) | 20 | 50 | 2.32 ± 0.17d |
a P < 0.05 (significance as compared to untreated), b P < 0.05 (significant as compared to parathion treatment), c P > 0.05 (nonsignificance as compared to untreated), and d P > 0.05 (nonsignificance as compared to untreated).
Figure 3Reduction in SCE frequency by curcumin against parathion treated cultured human lymphocytes. *P < 0.05 (significance as compared to untreated); P: parathion, Cu: curcumin, and DMSO: dimethyl sulphoxide.
Protective effect of carvacrol against parathion treated cultured human peripheral blood lymphocytes.
| Treatments | Concentrations used ( | Metaphase scored | SCE/cell ± SE |
|---|---|---|---|
| Control | Untreated | 50 | 2.46 ± 0.16 |
| Parathion | 2.5 | 50 | 5.63 ± 0.52a |
| Parathion + carvacrol | 2.5 + 2.5 | 50 | 4.33 ± 0.12b |
| Parathion + carvacrol | 2.5 + 5.0 | 50 | 3.07 ± 0.14b |
| Carvacrol | 2.5 | 50 | 2.56 ± 0.19c |
| Carvacrol | 5.0 | 50 | 2.86 ± 0.21c |
| DMSO (−ve control) | 20 | 50 | 2.32 ± 0.17d |
a P < 0.05 (significance as compared to untreated), b P < 0.05 (significant as compared to parathion treatment), c P > 0.05 (nonsignificance as compared to untreated), and d P > 0.05 (nonsignificance as compared to untreated).
Figure 4Ameliorative effect of carvacrol against parathion treated cultured human lymphocytes. *P < 0.05 (significance as compared to untreated), P: parathion, Ca: carvacrol, and DMSO: dimethyl sulphoxide.
Combined effect of curcumin and carvacrol against parathion treated cultured human peripheral blood lymphocytes.
| Treatments | Concentrations used ( | Metaphase scored | SCE/cell ± SE |
|---|---|---|---|
| Control | Untreated | 50 | 2.71 ± 0.22 |
| Parathion | 2.5 | 50 | 6.15 ± 0.65a |
| Parathion + curcumin | 2.5 + 10 | 50 | 4.59 ± 0.38b |
| Parathion + curcumin | 2.5 + 15 | 50 | 3.28 ± 0.24b |
| Parathion + carvacrol | 2.5 + 2.5 | 50 | 4.33 ± 0.12b |
| Parathion + carvacrol | 2.5 + 5.0 | 50 | 3.07 ± 0.14b |
| Parathion + curcumin + carvacrol | 2.5 + 10 + 2.5 | 50 | 5.08 ± 0.41c |
| Parathion + curcumin + carvacrol | 2.5 + 15 + 5.0 | 50 | 3.68 ± 0.31c |
a P < 0.05 (significance as compared to untreated).
b P < 0.05 (significant as compared to parathion treatment).
c P > 0.05 (nonsignificant as compared to curcumin and carvacrol alone treatment).
Figure 5Simultaneous effects of curcumin and carvacrol in SCE assay in human lymphocytes against parathion. *P: parathion, Cu: curcumin, and Ca: carvacrol.
Effect of GSTT1 and GSTM1 polymorphism on antigenotoxicity of curcumin and carvacrol against parathion induced genotoxicity.
| Genotype | Parathion (2.5 | Parathion (2.5 | Parathion (2.5 |
|---|---|---|---|
| Relationship with GSTT1 | |||
| GSTT1 (nonnull) | 5.90 ± 0.41 | 4.50 ± 0.35 | 4.26 ± 0.21 |
| GSTT1 (null) | 5.27 ± 0.38 | 3.85 ± 0.22a | 4.22 ± 0.10a |
|
| |||
| Relationship with GSTM1 | |||
| GSTM1 (nonnull) | 5.93 ± 0.85 | 4.36 ± 0.38 | 4.30 ± 0.15 |
| GSTM1 (null) | 6.00 ± 0.55 | 4.33 ± 0.66b | 4.43 ± 0.31b |
|
| |||
| Relationship with both GSTT1 and GSTM1 | |||
| GSTT1 (nonnull), GSTM1 (nonnull) | 4.80 ± 0.16 | 3.80 ± 0.17 | 4.20 ± 0.20 |
| GSTT1 (null), GSTM1 (null) | 5.45 ± 0.44 | 4.02 ± 0.0.34c | 4.15 ± 0.25c |
| GSTT1 (nonnull), GSTM1 (null) | 6.10 ± 0.40 | 4.35 ± 0.50 | 5.00 ± 0.17 |
| GSTT1 (null), GSTM1 (nonnull) | 6.50 ± 0.44 | 4.65 ± 0.45d | 4.26 ± 0.12d |
a P > 0.05 (nonsignificance as compared to GSTT1 nonnull genotypes).
b P > 0.05 (nonsignificance as compared to GSTM1 nonnull genotypes).
c P > 0.05 (nonsignificance as compared to GSTT1 and GSTM1 nonnull genotypes).
d P > 0.05 (nonsignificance as compared to GSTT1 nonnull and GSTM1 null genotypes).